Adial Pharmaceuticals announced it has been awarded an important patent which expands the estate covering the combination of the Company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder and drug dependencies, such as opioid use disorder, with the Company’s lead investigational new drug product AD04.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADIL:
- Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
- Adial Pharmaceuticals appoints Goodman as Chief Operating Officer
- Adial Announces Appointment of Tony Goodman as Chief Operating Officer
- Adial Pharmaceuticals files $100M mixed securities shelf
- Adial Pharmaceuticals receives final reimbursement payment from Adovate